Application 125117

Type
BLA
Sponsor
BIOMARIN

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125117Naglazymegalsulfase351(a)Rx2026-07-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001NAGLAZYMEGALSULFASEINJECTABLE; INJECTION5MG/5MLNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NAGLAZYMEGALSULFASEBioMarin Pharmaceutical Inc.59341250-deac-ed71-3823-a4f5d64dbd772024-09-18Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA125117
ndc (product): 68135-020

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 6 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
68135-020NAGLAZYMEgalsulfaseBioMarin Pharmaceutical Inc.BLACurrent
68135-020NAGLAZYMEgalsulfaseBioMarin Pharmaceutical Inc.BLACurrent
68135-020NAGLAZYMEgalsulfaseBioMarin Pharmaceutical Inc.BLACurrent
68135-020NAGLAZYMEgalsulfaseBioMarin Pharmaceutical Inc.BLACurrent
68135-020NAGLAZYMEgalsulfaseBioMarin Pharmaceutical Inc.BLACurrent
68135-020NAGLAZYMEgalsulfaseBioMarin Pharmaceutical Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
79614SUPPL 2024-09-16
79586SUPPL 2024-09-16
79078SUPPL 2024-07-15
79043SUPPL 2024-07-11
61363SUPPL2019-12-20
61329SUPPL2019-12-18
39848SUPPL2013-04-01
31836SUPPL2013-03-29
31835SUPPL2011-05-05
31834SUPPL2011-05-05
9613SUPPL2011-05-05
39847SUPPL2011-04-29
39846SUPPL2011-04-29
18794SUPPL2011-04-29
22785ORIG2005-09-13
18793ORIG2005-06-07
9612ORIG2005-06-07